Sickle Cell Treatment Demonstration Program

 

The objectives of this project is to support the development and establishment of systemic mechanisms to improve the prevention and treatment of sickle cell disease complications, including the coordination of service delivery for individuals with sickle cell disease; genetic counseling and testing; bundling of technical services related to the prevention and treatment of sickle cell disease; training of health professionals; and identifying and establishing efforts related to the expansion and coordination of education, treatment, and continuity of care for individuals with Sickle Cell Disease as authorized in 42 USC Section 300b-5(b) (Section 1106(b) of the Public Health Service Act).

Active 93.365 Health Resources and Services Administration, Department of Health and Human Services B - Project Grants Fiscal Year 2020 In FY 20, The Sickle Cell Treatment Demonstration Program served more than 25,000 individuals living with Sickle Cell Disease across the United States.
Fiscal Year 2021 Sickle Cell Treatment Demonstration Program served more than 25,000 individuals living with sickle cell disease(SCD) across the United States. Providers participating in the program prescribed hydroxyurea (a disease-modifying therapy) to 70% of their pediatric population and 14% of their pediatric population with other disease-modifying treatments. 57% of their adult patients received hydroxyurea prescriptions and 33% of their adult patients received other disease modifying therapy prescriptions. Furthermore, SCD providers indicated that 65% of eligible individuals with SCD (ages 2-16) had a transcranial doppler screening within the past 15 months, an important tool for detecting stroke risk which is elevated in individuals with SCD.
Fiscal Year 2022 In FY 20, the Sickle Cell Treatment Demonstration Program served more than 25,000 individuals living with sickle cell disease(SCD) across the United States. Providers participating in the program prescribed hydroxyurea (a disease-modifying therapy) to 70% of their pediatric population and 14% of their pediatric population with other disease-modifying treatments. 57% of their adult patients received hydroxyurea prescriptions and 33% of their adult patients received other disease modifying therapy prescriptions. Furthermore, SCD providers indicated that 65% of eligible individuals with SCD (ages 2-16) had a transcranial doppler screening within the past 15 months, an important tool for detecting stroke risk which is elevated in individuals with SCD. Public Health Service Act, Section 1106(b), 42 U.S.C. 300b-5(b) Eligible entities include, Federally-qualified health center, as defined in section 1905(10(2)(B) of the Social Security Act (42 U.S.C. 1396d(10(2)(B), nonprofit hospital or clinic, or university health center that provides primary health care, that: (1) has a collaborative agreement with a community-based Sickle Cell Disease organization or a nonprofit entity with experience in working with individuals who have Sickle Cell Disease; and (2) demonstrates that either the Federally-qualified health center, the nonprofit hospital or clinic, the university health center, the community-based Sickle Cell Disease organization or the Sickle Cell Disease experts who serve as consultants to the project have at least 5 years of experience in working with individuals who have Sickle Cell Disease. Projects will benefit individuals with Sickle Cell Disease and health professionals who provide care for individuals with Sickle Cell Disease. Applicants should review the individual HRSA notice of funding opportunity issued under this Assistance Listing program for any required proof or certifications which must be submitted prior to or simultaneous with submission of an application package. Preapplication coordination is required. This program is eligible for coverage under E.O. 12372, "Intergovernmental Review of Federal Programs." An applicant should consult the office or official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review. 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program. HRSA requires all applicants to apply electronically through Grants.gov. All qualified applications will be forwarded to an objective review committee. Based on the advice of the objective review committee, the HRSA program official with delegated authority is responsible for final selection and funding decisions. All qualified applications will be forwarded to an objective review committee. Based on the recommendations of the objective review committee, the HRSA program official with delegated authority is responsible for final selection and funding decisions. Notification is made in writing by a Notice of Award. Contact the headquarters or regional location, as appropriate for application deadlines From 120 to 180 days. Final decisions are made 4 to 6 months after receipt of applications. Not applicable. Competitive awards are typically made for up to 2 to 5 years, subject to the availability of funds. After initial awards, annual noncompetitive awards may be made contingent upon the submission of noncompetitive applications/progress reports and availability of funds and a determination that continued funding would be in the best interest of the federal government. Evaluation criteria vary based on the grant/cooperative agreement program. Refer to criteria included in the notice of funding opportunity for each specific program. All funds granted should be expended solely for carrying out the approved projects in accordance with Section 712 of the Public Law 103-357. Not applicable. In accordance with the provisions of 2 CFR 200, Subpart F - Audit Requirements, nonfederal entities that expend financial assistance of $750,000 or more in Federal awards will have a single or a program-specific audit conducted for that year. Non-Federal entities that expend less than $750,000 a year in Federal awards are exempt from Federal audit requirements for that year, except as noted in 2 CFR 200.503 Grantees are required to maintain grant accounting records 3 years after the date they submit the Federal Financial Review (FFR). If any litigation, claim, negotiation, audit or other action involving the award has been started before the expiration of the 3-year period, the records shall be retained until completion of the action and resolution of all issues which arise from it, or until the end of the regular 3-year period, whichever is later. Statutory formula is not applicable to this assistance listing.

Matching requirements are not applicable to this assistance listing.

MOE requirements are not applicable to this assistance listing. Refer to the notice of funding opportunity (NOFO). Awards are made annually, in accordance with the project period method of awarding grants. Payments are made through a Letter-of-Credit or Cash Demand System. Grantees drawdown funds, as necessary, from the Payment Management System (PMS). PMS is the centralized web based payment system for HHS awards. None/Not specified. Michael D Warren, Associate Administrator for Maternal and Child Health
5600 Fishers Lane
Rockville, MD 20857 US
MWarren@hrsa.gov
Phone: 301-443-2170 http://www.hrsa.gov 75-0354-0-1-550 (Cooperative Agreements) FY 22$4,999,996.00; FY 23 est $5,950,000.00; FY 24 est $5,000,000.00; FY 21$4,999,999.00; FY 20$4,237,486.00; FY 19$3,524,145.00; FY 18$3,474,358.00; FY 17$3,457,018.00; FY 16$3,327,345.00; - Cooperative Agreement FY 22 act. $900,000-$1,150,000; $1,000,000 FY 23 est. $1,100,000-$1,350,000; $1,247,803 FY 24 est. $900,000-$1,150,000; $1,000,000 This program is subject to the provisions of 45 CFR Part 92 for State, local and tribal governments and 45 CFR Part 74 for institutions of higher education, hospitals, other nonprofit organizations and commercial organizations, as applicable. HRSA awards are subject to the requirements of the HHS Grants Policy Statement (HHS GPS) that are applicable based on recipient type and purpose of award. The HHS GPS is available at http://www.hrsa.gov/grants. Not applicable.